Tolperisone: mechanism of action, clinical efficacy and safety in the treatment of musculoskeletal pain

Kukushkin M.L.

doi:https://doi.org/10.17116/pain20222002163

Close metadata

Recommended articles:

Muscle relaxant selection criteria for musculoskeletal pain. Russian Journal of Pain. 2024;(4):55-64

Control of neuropathic pain in lumbosacral dorsalgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):152-157

To the Question of Metronidazole Effectiveness in Rosacea Therapy. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):740-743

Efficacy and safety of topical antibiotic therapy in patients with acute external bacterial otitis: results of a retrospective study. Russian Bulletin of Otorhinolaryngology. 2024;(6):24-27

On the results of a multicenter, open, observational, non-interventional study of the efficacy and safety of nimesulide (Nise) in combination with muscle relaxants in patients with acute back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):82-88

Abstract:

The authors report data on mechanism of action, clinical efficacy and safety of non-benzodiazepine central muscle relaxant tolperisone in the treatment of musculoskeletal pain. Multiple-center randomized placebo-controlled trials proving clinical efficacy and safety of tolperisone in patients with acute non-specific back pain, myofascial pain syndromes and osteoarthritis are presented. It is emphasized that analgesic effect of tolperisone in the treatment of musculoskeletal pain, unlike other central muscle relaxants, is not accompanied by drowsiness. New reports devoted to slow-release tolperisone (Midocalm Long) are presented.

Keywords:

tolperisone

mechanism of action

clinical efficacy

Authors:

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Received:

10.03.2022

Accepted:

18.03.2022

Close metadata

References:

Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-1982. https://doi.org/10.1097/j.pain.0000000000001939
Yakhno NN, Kukushkin ML, Churyukanov MV, Davydov OS, Bakhtadze MA. New definition of pain by the International Association for the Study of Pain. Russian Journal of Pain. 2020;18(4):5-7. (In Russ.). https://doi.org/10.17116/pain2020180415
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990—2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2
Yakhno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. Results of an open multicenter study “MERIDIAN” to assess the prevalence of pain syndromes in outpatient practice and therapeutic preferences of doctors. Russian Journal of Pain. 2012;3-4:10-14. (In Russ.).
Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333.
Litwic A, Edwards M, Dennison E, Cooper C. Epidemiology and burden of osteoarthritis. British Medical Bulletin. 2013;105:185-199. https://doi.org/10.1093/bmb/lds038
Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment of musculoskeletal pain: interdisciplinary consensus. Scientific and Practical Rheumatology. 2016;54(3):247-265. (In Russ.).
Kukushkin ML, Brylev LV, Laskov VB, Makarov NS, Pizova NV, Sokov EL, Chefranova ZhYu, Sholomov II, Gekht AB. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(11):69-78. (In Russ.). https://doi.org/10.17116/jnevro201711711169-78
Csiba L, Zhussupova AS, Likhachev SA, Parfenov VA, Churyukanov MV, Guekht AB. Sistematicheskiĭ obzor po primeneniiu miorelaksantov pri boli v nizhneĭ chasti spiny A systematic review of using myorelaxants in treatment of low back pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(12):100-113. PMID: 30698569. (In Russ.). https://doi.org/10.17116/jnevro2018118121100
Fels G. Tolperisone: evaluation of the lidocaine-like activity by molecular modeling. Arch Pharm (Weinheim). 1996;329(4):171-178. PMID: 8669981. https://doi.org/10.1002/ardp.19963290402
Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-119. PMID: 18482024; PMCID: PMC6494009. https://doi.org/10.1111/j.1527-3458.2008.00044.x
Okada H, Honda M, Ono H. Method for recording spinal reflexes in mice: effects of thyrotropinreleasing hormone, DOI, tolperisone and baclofen on monosynaptic spinal reflex potentials. Jpn J Pharmacol. 2001;86(1):134-136.
Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn. 1984;7(3):171-176.
Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials: A comparative study. Neuropharmacology. 1989;28(2):161-173.
Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005;315(3):1237-1246. Epub 2005 Aug 26. PMID: 16126840. https://doi.org/10.1124/jpet.105.089805
Hinck D, Koppenhofer E. Tolperisone — a novel modulator of ionic currents in myelinated axons. Gen Physiol Biophys. 2001;20(4):413-429.
Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W. A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms. Eur J Pharmacol. 2006;538(1-3):5-14. Epub 2006 Mar 21. PMID: 16650844. https://doi.org/10.1016/j.ejphar.2006.03.034
Kukushkin ML, Khitrov NK. General pathology of pain. M.: Meditsina; 2004;144. (In Russ.).
Furuta Y, Yoshikawa A. Reversible adrenergic alpha-receptor blocking action of 2,48-dimethyl-3-piperidino-propiophenone (tolperisone). Jpn J Pharmacol. 1976;26:543-550.
Abranyi I. Study on the effect of 150-mg Mydocalm coated tablets in peripheral vascular diseases and in myotonias of various origin. Hungarian Medical Journal. 1988;36(2):56-61.
Briskin BS, Dibirov MD, Evseev YuN, Novoseltsev OS. Treatment of chronic arterial insufficiency of the lower extremities with midocalm in elderly and senile patients. Surgery. 2000;4:52-54. (In Russ.).
Briskin BS, Sakunova TI, Proshin AV, Yakobishvili YaI. Midocalm in the complex treatment of patients with diabetic foot syndrome. Clinical Gerontology. 2000;34:34-38. (In Russ.).
Devlikamova FI. Results of the post-registration study “PARUS” to assess the efficacy and safety of the drug Midocalm-Richter in local injection therapy of the myofascial trigger zone. Therapeutic Archive. 2018;6:81-88. (In Russ.). https://doi.org/10.26442/terarkh201890681-88
Shirokov VA, Yun OP, Bekhtereva EV. Effectiveness of local injectable therapy with midocalm for myofascial pain syndromes of the cervical-brachial region. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(6):78-80. (In Russ.).
Samartsev IN, Zhivolupov SA, Rashidov NA, Bardakov SN. Modern Approaches to Use Mydocalm for Local Injection Therapy of Pain Syndrome. Effective Pharmacotherapy. 2016;1:12-20. (In Russ.).
Fels G. Tolperisone: evaluation of the lidocaine-like activity by molecular modeling. Arch Pharm (Weinheim). 1996;329(4):171-8. PMID: 8669981. https://doi.org/10.1002/ardp.19963290402
Miskolczi P, Vereczkey L, Frenkl R. Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. J Pharm Biomed Anal. 1987;5(7):695-700.
Ovchinnikova EA, Rashid MA, Kulikov AYu, et al. Efficacy, safety and pharmacoeconomical aspects of tolperizone use. Practice. 2005;1:1-9. (In Russ.).
Feher M, Juvancz P, Szontagh M. Use of Mydocalm in the rehabilitation of hemiparetic patients. Blan Rehab Gyogyfurdougy. 1985;6:201.
Peja M. Mydocalm treatment in the rehabilitation of children with infantile cerebral palsy. Paediatrics. 1998;49(1):24-29.
Lashch NYu, Avakian GN. The use of Midocalm in patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;6:24-28. (In Russ.).
Avakian GN, Chukanova EI, Nikonov AA. The use of midocalm in the relief of vertebrogenic pain syndromes. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;5:26-31. (In Russ.).
Gurak SV, Parfenov VA, Borisov KN. Midocalm in the complex therapy of acute lumbar pain. Pain. 2006;3:27-30. (In Russ.).
Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996;67(2-3):417-425. PMID: 8951937. https://doi.org/10.1016/0304-3959(96)03187-9
Vaughan SA, Torres K, Kaye R. RESUME-1: A Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back. Pain Manag. 2022;12(1):25-33. Epub 2021 July 1. PMID: 34192885. https://doi.org/10.2217/pmt-2021-0041
Nalamachu S, Pergolizzi J, Kaye R. Tolperisone for the Treatment of Acute Muscle Spasm of the Back: Results from the Dose-Ranging Phase 2 STAR Study (NCT03802565). J Pain Res. 2020;13:3059-3069. Published 2020 Nov 23. https://doi.org/10.2147/JPR.S278857
Stamenova P, Koytchev R, Kuhn K, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005;12(6):453-461.
Parfenov VA, Bogdanov EI, Laskov VB, et al. Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):14-22. (In Russ.). https://doi.org/10.14412/2074-2711-2021-6-14-22
Dulin J, Kovacs L, Ramm S, et al. Evaluation of sedative effects of single repeated doses of 50 mg and 150 mg Tolperisone Hydrochloride. Results of prospective, randomized, double-blind, placebo-control trial. Pharmacopsychiatry. 1998;31(4):136-142.
Feher M, Lantos A, Denes Z, Vass M. Experiens with long term mydocalm (tolperison) therapy. Provisor (Rus). 2003;7. https://provisor.com.ua/archive/2003/N7/art_22.php?part_code=87&art_code=3589